4//SEC Filing
Longitude Capital Partners III, LLC 4
Accession 0000899243-20-002476
CIK 0001290149other
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 5:45 PM ET
Size
13.9 KB
Accession
0000899243-20-002476
Insider Transaction Report
Form 4
Longitude Capital Partners III, LLC
10% Owner
Transactions
- Conversion
Common Stock
2020-01-29+1,477,320→ 1,477,320 total(indirect: See Footnote) - Conversion
Series A Convertible Voting Preferred Stock
2020-01-29−19,500→ 0 total(indirect: See Footnote)→ Common Stock (1,477,320 underlying)
Footnotes (4)
- [F1]On January 22, 2020, a 1-for-40 reverse split of the Issuer's Common Stock (the "Reverse Split") was effected. These securities reflect the Reverse Split.
- [F2]Each share of Series A Convertible Voting Preferred Stock (the "Series A Preferred Stock") converted into 75.76 shares of the Issuer's Common Stock for no additional consideration, as adjusted for the Reverse Split, automatically upon the 5th trading date following the Issuer's announcement of receiving stockholder approval for the first reverse stock split of the Issuer following November 13, 2019. The Series A Preferred Stock has no expiration date.
- [F3]The reportable securities are owned directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson (a member of the Issuer's board of directors), are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F4]Consists of 19,500 shares of Series A Preferred Stock held by LVP III which are convertible into an aggregate of 1,477,320 shares of Common Stock, as adjusted for the Reverse Split.
Documents
Issuer
Sierra Oncology, Inc.
CIK 0001290149
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001713663
Filing Metadata
- Form type
- 4
- Filed
- Jan 30, 7:00 PM ET
- Accepted
- Jan 31, 5:45 PM ET
- Size
- 13.9 KB